Th e past decade of clinical and translational acute kidney injury (AKI) research has focused on the validation of novel biomarkers to detect AKI earlier, to ultimately provide researchers and clinicians with a much soughtafter golden window of opportunity to prevent AKI develop ment or mitigate its course. In the current study, Ricci and colleagues take the next logical step to use two novel biomarkers, neutrophil gelatinase-associated lipo calin (NGAL) and cystatin C, in a novel manner to defi ne AKI rather than predict AKI [1] . In their randomized trial, the investigators demonstrate the α 1 -selective dopa mine agonist fenoldopam to be associated with lower postoperative urinary NGAL and cystatin C concen trations compared with placebo. Furthermore, fenoldopam-treated children had a lower rate of reaching a urinary NGAL threshold of 200 ng/ml, suggesting its reno protective eff ects, despite no diff erences in creatinine-associated AKI development by the pediatric RIFLE criteria [2] .
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Children undergoing bypass represent an ideal model for AKI biomarker study since the timing of the kidney injury is known, interventions can be planned ahead of time, and children do not have many of the comorbidities of adulthood that can complicate studies [3, 4] . Previous trials of fenoldopam in children and adults to prevent serum-creatinine-defi ned AKI have had mixed results [5] [6] [7] [8] , with pediatric observational studies showing a benefi t in terms of enhanced urine output postoperatively. Th e chronological paradigm shift evaluating intraoperative agent administration to detect its eff ect on an early and sensitive marker of AKI such as NGAL provides a model for future randomized trials in this fi eld.
Importantly, the recent pooled analysis of 10 pediatric and adult studies by Haase and colleagues showing that 'NGAL-positive, serum creatinine-negative AKI' was asso ciated with equivalent or worse outcomes compared with 'creatinine-positive, NGAL-negative AKI' [9] provides strong support for Ricci and colleagues' decision to use NGAL to defi ne AKI. In fact, Haase and colleagues comment that 'in the absence of diagnostic increases in serum creatinine, NGAL detects patients with likely subclinical AKI who have an increased risk of adverse outcomes. Th e concept and defi nition of AKI might need re-assessment' [9] . In addition, patients treated with fenoldopam required fewer diuretics and vasodilators, demonstrating a clinically observable clinical benefi t of fenoldopam associated with the reduction in biomarker concentrations.
Abstract
Substantial basic and translational research has been directed to detect earlier and more sensitive acute kidney injury (AKI) biomarkers over the past decade. Much of the seminal AKI biomarker validation research has been performed in children undergoing cardiopulmonary bypass since they represent an ideal clinical model for AKI biomarker study: the timing of the injury is known and children do not have many of the co-morbidities seen in adult patient populations, which can confound the clinical situation. Ricci and colleagues report the results of their study using two novel urinary AKI biomarkers, neutrophil gelatinaseassociated lipocalin (NGAL) and cystatin C -not to predict AKI, but to defi ne it -in a randomized trial of intraoperative fenoldopam to prevent AKI. They demonstrate that fenoldopam administration led to decreased postoperative urine NGAL and urine cystatin C concentrations, suggesting a renoprotective eff ect. Given the high sensitivity of NGAL for AKI post cardiopulmonary bypass, this study provides a model to use novel AKI biomarkers in a novel manner. For the past decade, the assault on serum creatinine as an AKI biomarker has been relentless, with good reason, as adults and children with small rises in serum creatinine have increased risk of mortality and morbidity [10] [11] [12] , and we have recognized that patients are dying from AKI and not just dying with AKI [13] . Th e search for the renal troponin I or the renal brain natriuretic peptide has also led to the development of the concept of renal angina to identify patients at risk for AKI and to rule out patients not at risk who do not full the renal angina criteria [14] . Use of new biomarkers to defi ne AKI, or perhaps in future studies to enrich study populations to assess the eff ects of interventions on reducing AKI development and/or severity, has been the holy grail for AKI researchers to improve outcomes in critically ill patients at risk for AKI, or with AKI. Ricci and colleagues have, for possibly the fi rst time, connected the clinical and research sides of the translational research bridge with their current study. While future studies will need to confi rm their fi ndings in larger more complex cohorts, their work has brought AKI study out of the past and into an exciting present and future.
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